Mayne Pharma gets FDA tick for contraceptive pill

Adelaide-based pharmaceutical company Mayne Pharma is gearing up to sell its first novel oral contraceptive pill in the US by mid-year, with hopes to get the nod from the Australian regulator by early 2022.

Mayne Pharma reports $92 million loss

Adelaide-based pharmaceutical company Mayne Pharma has reported a $92.8 million loss for the 2020 financial year, driven by asset write downs in its generic medicines business.

Mayne Pharma CEO Scott Richards expects the new drug to be a long-term asset for women's health. Photo: AAP/Tracey Nearmy

Mayne Pharma shares rise over US deal

Mayne Pharma shares have soared 19 per cent to a near five-month high, after the Adelaide-based pharmaceutical company inked an exclusive long-term deal to sell a new contraceptive drug in the United States.

mayne pharma

Mayne Pharma gets FDA tick for contraceptive pill

Mayne Pharma reports $92 million loss

Mayne Pharma shares rise over US deal